Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.

This study aimed to investigate the clinical utility of simultaneous measurement of alphafetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for hepatocellular carcinoma (HCC) diagnosis in Chinese patients predominantly caused by hepatitis B virus infection by a multi-center case-controlled study. Subjects were 1,153 individuals from three major hospitals in China, including 550 cases in HCC group, 164 in Malignant disease group, 182 in Benign disease group, 85 in Chronic liver disease group, and 173 in Normal group. Serum levels of AFP and DCP were measured and clinicopathological features were determined for all subjects. Results showed that the levels of DCP and AFP were significantly higher in HCC group (550 patients, 74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating curves (ROC) indicated the optimal cut-off value was 86 mAU/mL for DCP with a sensitivity of 71.50% and specificity of 86.30%, and 21 ng/mL for AFP with a sensitivity of 68.00% and specificity of 93.20%. The area under ROC curve was 0.846 for DCP, 0.832 for AFP, and 0.890 for the combination of DCP and AFP. The combination of DCP and AFP resulted in a higher Youden index and a sensitivity of approximately 90%, even for small tumors. The simultaneous measurement of AFP and DCP could achieve a better sensitivity in diagnosing Chinese HCC patients, even for small tumors.

[1]  J. Bruix,et al.  Biomarkers for early diagnosis of hepatocellular carcinoma. , 2012, The Lancet Oncology.

[2]  S. Nakano,et al.  Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. , 1999, European journal of gastroenterology & hepatology.

[3]  H. Liebman,et al.  Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. , 1993, Hepatology.

[4]  J. Avery Critical review. , 2006, The Journal of the Arkansas Medical Society.

[5]  J. Kao,et al.  Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements , 2010, Journal of gastroenterology and hepatology.

[6]  J. Marrero Screening tests for hepatocellular carcinoma. , 2005, Clinics in liver disease.

[7]  C. Legnani,et al.  The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  J. Marrero Hepatocellular carcinoma. , 2005, Current opinion in gastroenterology.

[9]  M. Omata,et al.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review , 2008, Hepatology international.

[10]  S. Saab,et al.  Des‐γ‐carboxyprothrombin, α‐fetoprotein and AFP‐L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma , 2008, Journal of gastroenterology and hepatology.

[11]  P. Song,et al.  Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. , 2013, Hepatobiliary surgery and nutrition.

[12]  J. Marrero,et al.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.

[13]  Jianjun Gao,et al.  Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China , 2013, Liver Cancer.

[14]  J. Marrero,et al.  Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.

[15]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[16]  T. Ogihara,et al.  Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes , 1993, Digestive Diseases and Sciences.

[17]  Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma , 2000 .

[18]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[19]  N. Izumi Diagnostic and Treatment Algorithm of the Japanese Society of Hepatology: A Consensus-Based Practice Guideline , 2010, Oncology.

[20]  B. Furie,et al.  Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. , 1984, The New England journal of medicine.

[21]  Y. Ueno,et al.  Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. , 2000, The American journal of gastroenterology.

[22]  Jin-Lin Hou,et al.  Hepatocellular carcinoma in the Asia pacific region , 2009, Journal of gastroenterology and hepatology.

[23]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[24]  P. Song,et al.  The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011 , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[25]  Shou-Dong Lee,et al.  Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .

[26]  B. Daniele,et al.  α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .

[27]  K. Taketa,et al.  Determination of Optimum Cutoff Levels of Plasma Des-γ-Carboxy Prothrombin and Serum α-Fetoprotein for the Diagnosis of Hepatocellular Carcinoma using Receiver Operating Characteristic Curves , 1992 .

[28]  D. Amarapurkar,et al.  Application of surveillance programs for hepatocellular carcinoma in the Asia–Pacific Region , 2009, Journal of gastroenterology and hepatology.

[29]  J. Hoofnagle,et al.  Elevations in serum alpha‐fetoprotein levels in patients with chronic hepatitis B , 1989, Cancer.

[30]  K. Tanikawa,et al.  A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. , 2000, Oncology reports.

[31]  Hideo Tanaka,et al.  Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures , 2011, Journal of epidemiology.

[32]  H. Ding,et al.  Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. , 2002, Chinese medical journal.

[33]  B. Daniele,et al.  Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. , 2004, Gastroenterology.

[34]  Yuesi Zhong,et al.  Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. , 2013, Bioscience trends.

[35]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[36]  S. Fujiyama,et al.  Clinical usefulness of des-γ-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma , 1991, Digestive Diseases and Sciences.

[37]  H. Liebman,et al.  Des‐γ‐carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review , 1993 .

[38]  Yoichi M. Ito,et al.  Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size , 2006, The American Journal of Gastroenterology.

[39]  H. Ding,et al.  Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein , 2003, British Journal of Cancer.